Chambless 6 for the Atherosclerosis Risk in Communities (ARIC) Study Investigators Pathologic findings and cross-sectional epidemiologic studies suggest that past infection with Chlamydia pneumoniae is associated with clinical and subclinical atherosclerotic disease, although evidence from prospective studies is still scarce. The association between chronic infection by C. pneumoniae and incident coronary heart disease (CHD) was investigated in a case-cohort study conducted among participants in the Atherosclerosis Risk in Communities Study who were free of CHD at the baseline examination (1986)(1987)(1988)(1989). Levels of C. pneumoniae immunoglobulin G (IgG) antibodies in serum collected at baseline from 246 incident cases of CHD identified during follow-up (median, 3.3 years; maximum, 5 years) were compared with those from a stratified sample of the baseline cohort (n = 550). Among incident CHD cases, 65% had IgG antibody titers >1:64, compared with 55% of noncases (compared with negative IgG titers, the relative hazard of CHD was 1.6 (p < 0.01)). In multivariate analyses controlling for other risk factors (age, gender, smoking, serum cholesterol, hypertension, diabetes mellitus, and educational level), the above estimates were substantially reduced and became statistically nonsignificant (relative hazard = 1.2). A significantly increased CHD hazard associated with IgG antibody titers >1:64 was observed among nonsmokers, even after adjustment for other risk factors. Overall, these results do not provide strong support for the hypothesis that C. pneumoniae infection is a risk factor for clinical CHD. Studies with longer follow-up periods will be necessary to determine whether C. pneumoniae infection is involved as an etiologic factor in earlier phases of atherogenesis. Am J Epidemiol 1999; 150:149-56. atherosclerosis; Chlamydia pneumoniae; cohort studies; coronary disease; smoking Chlamydia pneumoniae (also known as Chlamydia TWAR) is a recently identified strain of Chlamydia that is frequently involved in acute respiratory infections in individuals of all ages (1-3). Evidence of past infection increases with age up to a level of 50-70 percent in different populations, and is consistently higher in males than in females (4, 5).
Pathologic findings and cross-sectional epidemiologic studies suggest that past infection with Chlamydia pneumoniae is associated with clinical and subclinical atherosclerotic disease, although evidence from prospective studies is still scarce. The association between chronic infection by C. pneumoniae and incident coronary heart disease (CHD) was investigated in a case-cohort study conducted among participants in the Atherosclerosis Risk in Communities Study who were free of CHD at the baseline examination (1986) (1987) (1988) (1989) . Levels of C. pneumoniae immunoglobulin G (IgG) antibodies in serum collected at baseline from 246 incident cases of CHD identified during follow-up (median, 3.3 years; maximum, 5 years) were compared with those from a stratified sample of the baseline cohort (n = 550). Among incident CHD cases, 65% had IgG antibody titers >1:64, compared with 55% of noncases (compared with negative IgG titers, the relative hazard of CHD was 1.6 (p < 0.01)). In multivariate analyses controlling for other risk factors (age, gender, smoking, serum cholesterol, hypertension, diabetes mellitus, and educational level), the above estimates were substantially reduced and became statistically nonsignificant (relative hazard = 1.2). A significantly increased CHD hazard associated with IgG antibody titers >1:64 was observed among nonsmokers, even after adjustment for other risk factors. Overall, these results do not provide strong support for the hypothesis that C. pneumoniae infection is a risk factor for clinical CHD. Studies with longer follow-up periods will be necessary to determine whether C. pneumoniae infection is involved as an etiologic factor in earlier phases of atherogenesis. Am J Epidemiol 1999; 150:149-56. atherosclerosis; Chlamydia pneumoniae; cohort studies; coronary disease; smoking Chlamydia pneumoniae (also known as Chlamydia TWAR) is a recently identified strain of Chlamydia that is frequently involved in acute respiratory infections in individuals of all ages (1) (2) (3) . Evidence of past infection increases with age up to a level of 50-70 percent in different populations, and is consistently higher in males than in females (4, 5) .
The presence of C. pneumoniae in atheromatous tissue from coronary, aortic, and carotid arteries has been demonstrated in most (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) but not all (17) studies. Furthermore, there is experimental evidence showing that C. pneumoniae multiplies in endothelial cells, smooth muscle cells, and macrophages (18, 19) , and the organism has been cultured from coronary atherosclerosis plaque tissue (16) .
Although some negative findings from crosssectional studies have been reported (20) , most crosssectional and case-control studies have shown that serologic evidence of past C. pneumoniae infection is associated with clinical or angiographically demonstrated coronary heart disease (21-26) and cerebrovascular disease (27) . Furthermore, higher antibody levels for C. pneumoniae have been found to be associated with greater subclinical atherosclerosis of the carotid arteries (28) .
The presence of C. pneumoniae in the plaque tissue and these cross-sectional associations, however, might be secondary rather than causative (29) (30) (31) . A temporal relation (i.e., the infection preceding atherosclerosis) remains to be demonstrated. Prospective studies of the relation between C. pneumoniae and clinical coronary heart disease are still scarce and offer inconsistent results. The first cohort study on the subject (32), a nested case-control study carried out among hypercholesterolemic participants in the Helsinki Heart Study cohort, found relatively weak, statistically nonsignificant associations between baseline antibody levels and incident coronary heart disease (maximum follow-up of 5 years), in contrast with stronger and significant associations with positive antibodies in serum obtained 6 months prior to the clinical event. Another 7-year prospective study (33) found conflicting results: a significantly elevated incidence of coronary heart disease in relation to C. pneumoniae in a cohort of nondiabetic subjects from Eastern Finland but not among nondiabetic subjects from Western Finland. In a recent randomized clinical trial among survivors of myocardial infarction (34) , C. pneumoniae seropositivity was associated with more frequent recurrence of cardiovascular events in a graded, dose-response fashion among placebo recipients but not among individuals treated with azithromycin, a macrolide antibiotic that is effective in treating C. pneumoniae respiratory infections. Similar results have been reported recently among patients with unstable angina who were treated with another antichlamydial antibiotic, roxithromycin, as compared with a placebo-treated group (35) . Furthermore, recent animal studies demonstrated that nasal inoculation of C. pneumoniae in rabbits induces aortic atherosclerosis (36, 37) , an effect that is prevented by azithromycin (37) .
The present study used data from the Atherosclerosis Risk in Communities (ARIC) Study to investigate the hypothesis that serum antibodies for C. pneumoniae are associated with incident coronary heart disease and that this association is independent of known cardiovascular risk factors.
MATERIALS AND METHODS

Study population
The main goals of the ARIC Study are to investigate the etiology and natural history of subclinical and clinical atherosclerosis (38) . The baseline study population consisted of 15,792 participants aged 45-64 years of both sexes who were initially examined between autumn 1986 and December 1989. These participants were randomly selected from four US communities (approximately one fourth from each): selected suburbs of Minneapolis, Minnesota; Washington County, Maryland; Forsyth County, North Carolina; and Jackson, Mississippi. The first two communities are predominantly White. Blacks were sampled exclusively in Jackson and comprised 12 percent of the study sample from Forsyth County.
For the present analyses, subjects of races other than White or Black (n = 48) as well as participants with evidence of or missing information on prevalent clinical cardiovascular disease at baseline (history of physiciandiagnosed myocardial infarction or coronary surgery, Q-wave findings on the 12-lead electrocardiogram, or history of cerebrovascular disease (n = 1,338)) were excluded. The remaining 14,406 participants constituted the sampling frame for the present analyses. Among eligible cohort participants, a stratified random sample (n = 556) was selected for this nested study. The criteria for the strata were age (10-year groups), gender, and carotid artery intima-media wall thickness (above or below 0.67577 mm) as measured by B-mode ultrasound (see below). Certain strata were overrepresented so that we could obtain enough subjects for parallel case-control comparisons in other ARIC investigations. The sampling fractions were taken into account in all statistical analyses in the present report.
Follow-up procedures and definition of events
ARIC follow-up methods have been described in detail elsewhere (39) . Possible coronary heart disease events were ascertained either by annual telephone interviews, by triennial follow-up visits, or by routine surveillance of death certificates and discharge lists from local hospitals. Out-of-hospital deaths were investigated in most cases by interviews with next of kin and by questionnaires completed by the patients' physicians. Coroner reports and autopsy records, when available, were obtained for validation. For hospitalized patients, trained abstractors recorded all discharge diagnoses and procedure codes, the presenting signs and symptoms (including chest pain), cardiac enzyme levels, and related clinical information. Technicians visually coded up to three 12-lead electrocardiograms using the Minnesota code (40) , and they evaluated wave-form evolution using side-by-side comparisons. An ARIC Morbidity and Mortality Classifications Committee then reviewed and adjudicated all potential clinical coronary heart disease events using previously published criteria (39) . An incident coronary heart disease event was defined as 1) a definite or probable myocardial infarction (including silent myocardial infarction), 2) a definite coronary heart disease death, or 3) coronary revascularization (a hospital procedure code including coronary bypass, coronary angioplasty, or coronary atherectomy). To maximize the specificity of the event definition, angina was not considered.
The present analyses relate to incident coronary heart disease events that occurred among individuals in the eligible cohort (n = 14,406) between the baseline visit (fall 1986-end of 1989) and December 31, 1991 (median follow-up time, 3.3 years; maximum, 5.1 years). A total of 257 incident coronary heart disease events were identified during that period.
The baseline examination took place at the study clinic in each community, after a home interview was administered by trained interviewers. Information on education (highest grade completed), cigarette smoking, and medical history was obtained from the interview. Medication use was assessed by asking each participant to bring to the study clinic all medications taken during the previous 2 weeks.
Blood pressure measurements, anthropometric measurements, and venipuncture were carried out after subjects had fasted for at least 12 hours. Systolic and diastolic blood pressure were calculated as the average of the second and third of three consecutive measurements made with a random-zero sphygmomanometer. Hypertension was defined as a systolic blood pressure >140 mmHg, a diastolic blood pressure >90 mmHg, or use of antihypertensive medication. The presence of carotid atherosclerosis was assessed using B-mode ultrasound examination of the carotid arteries by trained sonographers following a standardized protocol (38, 41) . Measurements of the intima-media thickness (in mm) of the far wall of the carotid arteries were taken at the common and internal carotid arteries and the bifurcation. The ultrasound images were recorded on tape and sent to the central ARIC Ultrasound Reading Center at Bowman-Gray School of Medicine (Winston-Salem, North Carolina), where they were read by trained personnel. The average intima-media thickness of all measurements of the carotid artery far wall was used as a measure of carotid atherosclerosis.
Blood specimens were drawn and processed following a protocol described in detail elsewhere (38) . Aliquots were centrifugated, frozen at -70°C, and shipped to the ARIC central laboratories. Plasma total cholesterol was measured by enzymatic methods (42) . Hypercholesterolemia was defined as either a plasma cholesterol level >240 mg/dl or use of lipid-lowering medication. Serum glucose was assessed by the hexokinase method. Prevalent diabetes mellitus was defined as a fasting glucose level >140 mg/dl, a nonfasting glycemia level >200 mg/dl, and/or previous antidiabetic treatment or a diabetes history.
Levels of immunoglobulin G (IgG) for C. pneumoniae were measured by microimmunofluorescence (2) in Dr. J. T. Grayston's laboratory at the University of Washington (Seattle, Washington). Laboratory personnel were masked as to the case/control status of the samples. Antibody results were classified into the following three categories based on their distribution (see figure 1 ): "negative," "low positive" (titers of 1:8-1:32), and "high positive" (titers >1:64). This classification has been previously used in other studies (10, 24, 34 
Statistical analyses
The sampling strategy for this study was based on a case-cohort design. The stratified character of the baseline cohort sample determined that all means and proportions were estimated taking into account the sampling fractions using SUDAAN (43) . Among the 550 members of the cohort sample, 10 were also part of the incident coronary heart disease group, while the remaining 236 cases were not part of the cohort sample. To account for the case-cohort sampling, we used the method of Barlow (44), with the sampling fractions in the cohort varying by age group/gender/carotid wall thickness strata. Cases outside of the cohort sample were entered into the analysis immediately prior to their occurrence (staggered entries), and robust variance estimates corresponding to this analytic strategy were obtained following Barlow's algorithm, which uses the proportional hazards regression procedure PHREG in the Statistical Analysis System (SAS Institute, Cary, North Carolina). We used the latter method in an attempt to control for potential confounders of the association between C. pneumoniae infection and coronary heart disease (e.g., demographic factors, socioeconomic status, and smoking). In addi-tion, to determine whether this association is mediated in part by the putative atherogenic effects of C. pneumoniae infection, rather than more acute effects (e.g., thrombosis), adjustment for carotid intima-media thickness was also attempted. The potential interaction between antibody levels and other covariates (e.g., smoking) was examined by adding interaction terms to the regression models and testing the statistical significance of the corresponding coefficient.
RESULTS
The 246 cases with complete information for the present analyses were distributed as follows: 190 cases of hospitalized myocardial infarction or fatal coronary heart disease, 37 coronary revascularization procedures, and 19 silent myocardial infarctions. Cases were older, were more frequently male, and included a slightly higher proportion of Blacks in comparison with the entire cohort sample or the noncases (table 1) . As expected, cases were also less educated, more likely to be current smokers, and more frequently hypertensive, hypercholesterolemic, and diabetic at the baseline ARIC examination.
As figure 1 shows, cases had a higher frequency of IgG seropositivity than did noncases. The frequency of Since the cohort sample was selected as a representative sample of the entire ARIC cohort, the association of IgG seropositivity (>1:64) with other coronary heart disease risk factors was examined in this group (table 2) . There were no statistically significant differences in positivity for IgG antibodies according to age, gender, or race. Smokers (current or former) were significantly more likely to have IgG antibodies than never smokers. Hypertension and diabetes were also associated with a statistically nonsignificant higher prevalence of IgG titers >1:64, while there were practically no difference according to cholesterolemia or educational level. Other cutoff points produced results similar to those presented in table 2 (data not shown).
Unadjusted relative hazard estimates showed a 60 percent increased coronary heart disease incidence associated with high levels of IgG antibodies, compared with negative titers. When adjusted for gender, age, and study center, the relative hazard estimate for high levels of IgG remained at 1.6, and some evidence of a "dose-response" relation with levels of IgG antibodies remained evident (table 3) . When adjustment for all of the covariates described in tables 1 and 2 was carried out, however, the association essentially disappeared. Adjustment for carotid intima-media thickness also weakened the estimated hazard ratio for IgG titers >1:64 (hazard ratio = 1.4), although not as much as was seen after adjustment for the risk factors. In order to explore which of the risk factors included in the adjusted models in table 3 accounted for the drop in the estimated relative hazards, we sequentially entered all of these risk factors into adjustment models. Adjustment for cigarette smoking, particularly when combined with adjustment for hypertension, was the covariate with the largest impact on the drop of the adjusted relative hazard estimates (data not shown). Once these two variables were controlled, in addition to the demographic factors, the relative hazard for IgG titers >1:64 compared with negative titers was 1.3 (95 percent confidence interval 0.8-2.2), and further adjustment for pack-years of smoking and for the other risk factors did not materially change this result.
When data were stratified by smoking status (table  4) , the association between positive C. pneumoniae antibodies and coronary heart disease incidence was present only among never smokers. Furthermore, in the fully adjusted model, the association among never smokers (relative hazard = 3.3) was significantly different (p for interaction = 0.02) from the association among ever smokers (relative hazard = 0.9). When smoking was characterized as "current" versus "noncurrent," the effect was still present only in the nonsmoking group, and the interaction was also statistically significant in the fully adjusted model (p = 0.04). Analyses excluding persons with diabetes resulted in estimates of association that were similar to (or slightly weaker than) those shown in table 3. Stratification by other potentially important covariates such as age, gender, hypertension, hypercholesterolemia, and educational level resulted in unstable and inconsistent estimates, possibly because of limited power due to small numbers (data not shown).
Since incident coronary heart disease and coronary revascularization may have different determinants, the analyses shown in table 3 were also conducted after exclusion of the coronary revascularization cases (n -37). These analyses resulted in even weaker estimates than those shown above; the relative hazards for IgG titers >1:64 compared with negative titers were 1.3, 0.8, and 1.3 after adjustment for demographic factors, demographic factors plus risk factors, and demographic factors plus carotid intima-media thickness (as in table 3), respectively.
DISCUSSION
This was the third and largest prospective study on the relation between C. pneumoniae infection and incident coronary heart disease. Among individuals who were free of clinical evidence of coronary heart disease at baseline, we found that serum levels of antibodies against C. pneumoniae tended to be higher in those who subsequently developed coronary heart disease over a follow-up period of approximately 3.3 years, on average (maximum, 5 years). However, this association was weakened and became statistically nonsignif- Adjusted for demographic factors and carotid artery intima-media thickness* * Estimated using weighted proportional hazards regression models with staggered entries for cases outside of the subcohort and Barlow's (44) robust variance estimates (see "Materials and Methods").
t Reference category. $ RH, relative hazard; Cl, confidence interval. § Age (continuous variable), gender, race, and study center. H Smoking, hypercholesterolemia, hypertension, diabetes mellitus, and educational level, all defined using indicator variables to characterize the levels as in table 1.
# Carotid intima-media thickness was measured by B-mode ultrasound as a continuous variable. icant after we controlled for cardiovascular disease risk factors, particularly smoking and hypertension.
These results are consistent with those reported in the first prospective study of C. pneumoniae infection as a cardiovascular risk factor among participants in the Helsinki Heart Study (32) . Although the Finnish study is frequently quoted as demonstrating an independent association between C. pneumoniae seropositivity and incident coronary heart disease, a significant association was found in that study only for serum antibody levels measured 3-6 months prior to acute myocardial infarction; when baseline serum antibody levels were used, the risk factor-adjusted associations between IgG antibodies and incident coronary heart disease were largely statistically nonsignificant (32) .
In the other prospective study (33) , an association between C. pneumoniae antibodies and incident coronary heart disease was seen only among nondiabetic subjects in one of the two cohorts studied. In the present study, analyses restricted to subjects without diabetes at the initial ARIC visit yielded results essentially identical to those seen in the entire cohort (table 4) .
The hypothesis of a causal association between C. pneumoniae infection and atherosclerosis is consistent with pathologic and laboratory evidence showing that this microorganism can infect the cells present in atherosclerotic tissue (6-16, 18, 19) , and it is biologically plausible (4, 30) . On the other hand, the infection of the plaque tissue could be secondary to cell damage occurring before and during the pathophysiologic process of atherosclerosis (29) (30) (31) . It has been suggested that the association between C. pneumoniae and atherosclerosis may be the result of confounding, particularly by smoking (31, 45, 46) . In our study, as in previous studies (32, 46, 47) , C. pneumoniae antibodies were more frequently found among smokers than among nonsmokers, although not all studies have shown such a relation (24, 33, 48) . Adjustment for other risk factors and for smoking in particular did result in a substantial decrease in the estimated coronary heart disease hazard ratio associated with C. pneumoniae infection in this study. The residual weak association observed after multivariate adjustment might be the result of residual confounding by other lifestyle or constitutional correlates not controlled for in the present study and in previous studies.
On the other hand, it has been speculated that C. pneumoniae infection might be one of the mechanisms by which smoking is associated with coronary heart disease (49) . If smoking relates to coronary heart disease through promotion of C. pneumoniae respiratory tract infection, an interaction effect between smoking and C. pneumoniae antibodies would be expected. In fact, Thorn et al. (48) found that an association between C. pneumoniae antibodies and angiographically defined coronary heart disease was limited to cigarette smokers. Moreover, unpublished data from the Helsinki Heart Study also show that "smoking did have a more than additive effect with markers of C. pneumoniae infection" (50). We could not confirm this finding in the present study, however. On the contrary, an elevated risk of coronary heart disease related to high levels of C. pneumoniae antibodies in our study seemed to be limited to nonsmokers (table 4) . We are unsure about the importance of this finding, given that it contradicts previous data and is based on a small number of cases in this group.
The principal strengths of the present study stem from its prospective nature, from the fact that it is populationbased, and from the highly standardized methods of data collection used both at baseline and for the ascertainment of incident coronary heart disease events (40, 41) . Its main limitation derives from the relatively short follow-up time (a median of 3.3 years) and the relatively small number of coronary heart disease events. Another limitation stems from the use of serum antibody levels as an indicator of C. pneumoniae infection. High levels of positive IgG antibodies may indicate frequent or recent reactivation of C. pneumoniae chronic infection. The predictive value of negative antibodies, however, is somewhat limited, since C. pneumoniae has been found in plaques of seronegative individuals (10, 15) . The misclassification introduced by using this imperfect surrogate measure of infection may have biased our results towards the null hypothesis, perhaps In summary, in the present study, evidence of chronic C. pneumoniae infection associated with incident coronary heart disease was present in unadjusted analyses. The association seemed to be confounded by other cardiovascular disease risk factors, particularly cigarette smoking. Because of the relatively short follow-up period, the only conclusion we can draw from the present results is that C. pneumoniae may not be a strong risk factor for the triggering of acute coronary heart disease events, i.e., during the late stages in the natural history of coronary atherosclerotic disease (e.g., thrombosis, precipitation of acute ischemic events). This conclusion is ostensibly in conflict with results from recent trials showing a significant short term reduction of cardiovascular events in individuals with clinical coronary heart disease who are treated with antibiotics effective against C. pneumoniae (34, 35) , although it is not entirely clear whether this reduction is related to effects other than the anti-C pneumoniae action of the antibiotic (e.g., reduction of intercurrent infections, antiinflammatory activity) (34-36,51,52).
As is discussed elsewhere (53), C. pneumoniae may be only one of many infectious agents potentially involved in atherosclerosis. We believe that, given the ample breadth of evidence from experimental, pathologic, and epidemiologic studies, the possible role of C. pneumoniae and other infections in earlier or late phases of atherogenesis requires further investigation.
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